Colonel William A. Phillips

Add links

Basmisanil (INNTooltip International Nonproprietary Name; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.[1][2][3] As of June 2016, it is no longer studied for this purpose.[4] It underwent a clinical trial for cognitive impairment in patients with schizophrenia.[5]

See also

References

  1. ^ Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". Journal of Alzheimer's Disease. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
  2. ^ Hurley D (2013). "Investigators Silence Trisomy 21 Chromosome in Human Down Syndrome Cells". Neurology Today. 13 (17): 14–15. doi:10.1097/01.NT.0000434604.55014.fd. ISSN 1533-7006.
  3. ^ Jensen HS, Nichol K, Lee D, Ebert B (2014). "Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes". PLOS ONE. 9 (2): e88456. Bibcode:2014PLoSO...988456J. doi:10.1371/journal.pone.0088456. PMC 3922815. PMID 24533090.
  4. ^ Chevrette M. "Response to the Roche Clinical Trial for CLEMATIS". Retrieved 2016-06-28.
  5. ^ Clinical trial number NCT02953639 for "A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics" at ClinicalTrials.gov

External links

source: https://en.wikipedia.org/wiki/Basmisanil